Market Intelligence, Clinical Progress, and High-Purity Reagents for Inflammatory Disease, Oncology, and Autoimmune Disease Development.
TarMart Solution Ecosystem & Related Targets
Comprehensive reagent toolkit for PTGER4 (EP4) drug discovery. Select your modality below:
| Component / Network | Product Description | Product Link |
|---|---|---|
| Gene Delivery | PTGER4 Lentivirus (Premade Particles) Full-length ORF for stable cell lines. HEK293 expressed, native glycosylation. High titer, sequence verified. |
View PTGER4 Products |
| Validator | PTGER4 siRNA Set For knockdown verification and specificity controls. |
View PTGER4 Products |
| Selectivity Panel | PTGER1 (EP1) Lentivirus – Counter-screening calcium signaling. Sequence Verified. | View PTGER1 Products |
| Selectivity Panel | PTGER2 (EP2) Lentivirus – Counter-screening cAMP competition. High Purity. | View PTGER2 Products |
| Selectivity Panel | PTGER3 (EP3) Lentivirus – Gi pathway selectivity assessment. Endotoxin Controlled. | View PTGER3 Products |
| Pathway Partner | PTGS2 (COX-2) Recombinant Protein – Upstream enzyme control for PGE2 synthesis. >95% purity. | View PTGS2 Products |
| Benchmark Ab | Anti-PTGER4 Recombinant Control – High purity (>95%), low endotoxin (<1EU/ug). | View PTGER4 Products |
| Related Target | PDCD1 – Immune checkpoint often combined with PTGER4 antagonism in solid tumors. | View PDCD1 Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| GPCR Conformation Integrity | Full-length PTGER4 Lentivirus with native membrane insertion and 7-TM topology preservation |
| Subfamily Selectivity (EP1/2/3 vs EP4) | Ortholog panel: Human/Mouse/Rat PTGER1-4 available for cross-reactivity matrices |
| Pathway Validation | Gs-coupled cAMP assay ready; Theoretical MW verified; Sequence Verified ORF |
| False Positives | Validated siRNA included for PTGER4 knockdown specificity confirmation |
Live PTGER4 R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The race for PTGER4 (EP4) therapeutics is intensifying. Major players are shifting focus from broad COX inhibition to selective EP4 antagonism for improved GI safety profiles. First-generation small molecules are advancing through Phase II for ulcerative colitis, while the next wave of R&D targets combination strategies with checkpoint inhibitors and precision pain management. Simultaneously, the role of PGE2 in tumor immune evasion has driven major oncology players to develop PTGER4 antagonists in combination with PD-1/PD-L1 inhibitors to overcome resistance in solid tumors. Emerging modalities include monoclonal antibodies and agonists for bone healing.
Competitive Modality & Indication Snapshot
Connect market trends to assay needs.
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Small Molecule Antagonist (GI/Pain) | Eicos Sciences, Novartis, Merck | Ulcerative Colitis, Pain | cAMP Inhibition Assay (Need functional GPCR expression) |
| Small Molecule Antagonist (Oncology) | Ono Pharma, Eisai, Corvus | Solid Tumors, CRC | cAMP/Calcium Flux Assays (Need Lentivirus for Cell Lines) |
| Combination Therapy (IO) | BMS, Roche | Immuno-Oncology | Cell-based selectivity panel (EP1-4) |
| Monoclonal Antibody | Emerging Biotechs | Immunotherapy combos | FACS Binding (Need native receptor expression) |
| Topical Formulations | Derm-focused biotechs | Dermatitis | Permeability assays with native membrane context |
| Agonist | Kaken Pharma | Bone healing, Ulcerative Colitis | Functional Activation (Need high-titer Lentivirus) |